Stock listing

NASDAQ:WWB Windward Bio Group AG Stock

Home listing (NASDAQ) of Windward Bio Group AG

Follow Windward Bio Group AG into a list and get an email when it puts out news.

Share price · NASDAQ:WWB

$24.29 USD +1.64 (+7.3%)

Close on Nov 20, 2026

Past month +42.9% · daily closes, Nov 12, 2026 – Nov 20, 2026, adjusted for splits
Day range
$22.47 – $26.20 USDNov 20, 2026
Volume
158,585 sharesNov 20, 2026
Market cap
$1.41B USDAt the close on Nov 20, 2026 · price × 58.04M shares outstanding

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:WWB · Home$24.29 USD+1.645 (+7.3%)158,585$24.49$26.20$22.47$22.64Close on Nov 20, 2026

Daily closes

Last 3 months, Nov 12, 2026 – Nov 20, 2026 · NASDAQ:WWB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$24.29+1.645+7.3%$24.49$26.20$22.47158,585
$22.64-3.12-12.1%$25.51$29.92$21.02518,148
$25.76-4.28-14.2%$29.67$29.67$21.38246,200
$30.04+1.54+5.4%$25.00$32.00$22.50237,700
$28.50+11.50+67.6%$18.35$33.99$18.351,279,000
$17.00——$17.00$17.00$17.000
Ticker
NASDAQ:WWB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Windward Bio Group AG news

Windward Bio Group AG on 6ix

Sector
Health care
Industry
Biotechnology
News releases
3 in the last 12 months · 3 in all · newest Nov 17, 2026 · oldest 2026

Where Windward Bio Group AG is listed

ListingExchangeCountryCurrency
NASDAQ:WWB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:WWBBOATSUnited StatesUSD

Team and board

Officers

OfficerRole
Luca SantarelliChief Executive Officer, Founder & Chair of the Board
Claudia D’AugustaChief Financial Officer
Sandip KapadiaExperienced Life Sciences Board Member and Chief Financial Officer
Kevin HarrisChief Operating Officer
Scott ApplebaumChief Legal & Corporate Development Officer
Martine MazzettiChief of Staff
Michael SteiningerChief Human Resources Officer
Omar KhwajaChief Medical Officer
Otello StampacchiaFounder & Managing Director, Omega Fund Management, LLC

Board

DirectorRole
Luca SantarelliChief Executive Officer, Founder & Chair of the Board

Financings

RaiseDate
Public offering of common shares
Closed: US$17 a share · Jefferies +3
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Piper Sandler (co-lead), UBS Investment Bank (co-lead)
Nov 16, 2026
Private placement of common shares and pre-funded warrants
Closed: US$50M raised
Buyers: Sanofi Foreign Participations B.V. (1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares for $50.0 million)
Nov 16, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Nov 12, 2026.

Price
US$17.00 a share
Shares offered
10,294,117 common shares
Offering size
US$175 million
Underwriters' option
Up to 1,544,117 more shares
Listing
WWB on the Nasdaq Global Select Market
Underwriters
Jefferies, TD Cowen, Piper Sandler, UBS Investment Bank · In the order on the cover
Shares delivered
On or about Nov 16, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceJul 24, 2026
Filed publiclyOct 23, 2026
Amended twiceNewest Nov 9, 2026
Shares registered with an exchangeNov 9, 2026
Declared effective by the SECNov 12, 2026
Final prospectus, with the priceNov 16, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Nov 16, 2026

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
All 37 filings
FilingDateTypeFiled with
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
6-K · Report of a foreign issuerNov 16, 2026Current reportSEC
424B4 · ProspectusNov 13, 2026Offer documentSEC
S-8 · Registration statement for employee plansNov 13, 2026Offer documentSEC
S-8 · Registration statement for employee plansNov 13, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 13, 2026Other filingsSEC
3 · Initial statement of ownershipNov 12, 2026Insider tradeSEC
FWP · Free writing prospectusNov 12, 2026Offer documentSEC
3 · Initial statement of ownershipNov 12, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 12, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 12, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 12, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 12, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 12, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 12, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 12, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 12, 2026Insider tradeSEC
CERT · Exchange's certificate of listingNov 12, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeNov 9, 2026Other filingsSEC
F-1/A · Registration statement, amendedNov 9, 2026Offer documentSEC
F-1/A · Registration statement, amendedOct 30, 2026Offer documentSEC
F-1 · Registration statementOct 23, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedOct 13, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedSep 21, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedAug 27, 2026Offer documentSEC
DRS · Draft registration statementJul 24, 2026Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Windward Bio Group AG’s releases · as of Nov 16, 2026

Common shares
58,038,748
Fully diluted
58,038,748

Fully diluted

LineSharesAs of
Common shares58,038,748Nov 16, 2026

Share count over time

CountShares
Nov 16, 202658,038,748

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Orbimed Advisors LLC
Director, 10% owner
Buy1,176,471USD 17.00US$20MNov 16, 2026
Bonita David P
Director, 10% owner
Buy1,176,471USD 17.00US$20MNov 16, 2026
Stampacchia Otello
Director
Buy875,000USD 17.00US$14.9MNov 16, 2026
Stampacchia Otello
Director
Buy875,000USD 17.00US$14.9MNov 16, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Bonita
Other companies: Third Harmonic Bio Inc. (Director · Since at least Aug 11, 2025); ImageneBio, Inc. (Director · Since at least Jul 25, 2025); Prelude Therapeutics Incorporated (Director · Since at least Jun 12, 2025)
Director · Since at least Nov 16, 2026
Claudia D’AugustaChief Financial Officer · Since at least Nov 16, 2026
Kevin HarrisChief Operating Officer · Since at least Nov 16, 2026
Luca SantarelliChief Executive Officer, Founder & Chair of the Board · Since at least Nov 16, 2026
Martine MazzettiChief of Staff · Since at least Nov 16, 2026
Michael SteiningerChief Human Resources Officer · Since at least Nov 16, 2026
Omar KhwajaChief Medical Officer · Since at least Nov 16, 2026
Otello StampacchiaDirector · Since at least Nov 16, 2026
Sandip KapadiaDirector · Since at least Nov 16, 2026
Scott ApplebaumChief Legal & Corporate Development Officer · Since at least Nov 16, 2026

Open People

Log in to ask 6ix AI your own questions about Windward Bio Group AG.